Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
09/06/2026
The National Film and Video Foundation (NFVF) is a statutory body mandated to spearhead the equitable growth and development of the South African film and video...
09/06/2026
The BBC has found its Hercule Poirot.
After Deadline revealed last month that t...
09/06/2026
Media buyers and sellers can now compare YouTube reach from computer, mobile, an...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
A project aimed at modernizing scheduling operations across Mediaset's channel portfolio
Mediagenix, a global leader in smart content solutions to profitab...
09/06/2026
tvONE, an ACT Entertainment brand, debuts its most powerful video processor ever built: the 4RU CALICO PRO (C7-PRO-4200), at InfoComm 2026 (Booth N6813). Engine...
09/06/2026
Composer and Conductor Eric Whitacre to Receive Honorary Doctorate at Berklee Va...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Technology collaboration to validate AMPP and Lawo HOME orchestration integration, showcasing Dynamic Media Facility principles in practice.
Grass Valley and ...
09/06/2026
Bitmovin, a leading provider of video streaming solutions, today announced that Axel Springer SE, international media and technology company, has deployed Playe...
09/06/2026
LiveU, the global leader in live IP-video solutions, today announced a landmark deployment with the Oceania Football Confederation (OFC) that has brought Video ...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
09/06/2026
Two Alumni Win Tony Awards Mike Morris and Cedric Leiba Jr. won awards for Best Orchestrations and Best Play, respectively.
June 8, 2026
By
Tori Donahue
...
09/06/2026
Back to All News
Netflix Unveils First Images And Poster For Wrath, A New Brazi...
09/06/2026
Enni Continues to Rely on Arvato Systems - And Will Be Using AEP.EnerS4 Billing Solution
Arvato Systems to implement transformation project for SAP S/4HANA Ut...
09/06/2026
These special programmes will highlight RT 's connection with the Irish diaspora
This year, RT is marking 100 years of public broadcasting in Ireland with...
08/06/2026
The two execs discuss the goals and the challenges of building a huge multi-cult...
08/06/2026
This industry legend has been a road warrior since the early '90s and is, today, a lynchpin on College GameDay
The sports-production industry continues to ...
08/06/2026
DAZN has agreed a multi-year rights partnership with Extreme Fighting Championship (EFC), expanding its global combat sports portfolio.
DAZN will broadcast EFC...
08/06/2026
As fans move across broadcast, streaming, social, mobile and creator-led platforms, and they expect every angle, in real time, TVU Networks has released a new e...
08/06/2026
Infront has further strengthened the 2026 Diamond League's international bro...
08/06/2026
Grass Valley has announced the appointment of Sam Craig as Vice President, Global Pre-Sales. Based in the United States, Craig will lead Grass Valley's glob...
08/06/2026
SMPTE has announced its summer 2026 education lineup covering IP networking and SMPTE ST 2110, including two standalone courses, a 13-week boot camp, and a hand...
08/06/2026
Sportradar Group AG has announced a multi-year global agreement with Kalshi, a p...
08/06/2026
FIFA and Gamefam have announced the launch of a FIFA World Cup 2026 event on Roblox, running June 5 through July 31, 2026. The event centers on FIFA Super Socce...
08/06/2026
A collaboration of NHL Productions, Monumental Sports, and Michael Levitt Produc...
08/06/2026
CBS Sports production staffer Bryce Adair has died at the age of 31 after sustaining injuries during a car accident on Wednesday while in Ohio working the the P...
08/06/2026
Behind The Mic provides a roundup of recent news regarding on-air talent, including new deals, departures, and assignments compiled from press releases and repo...
08/06/2026
WMT Digital today announced the launch of WMT Fan Intelligence, designed to unif...
08/06/2026
The Heat are the seventh NBA team to air their games over-the-air next season...
08/06/2026
Paramount and UFC have announced an expansion of their media rights partnership making Paramount the exclusive home of UFC Numbered Event main cards in Canada ...
08/06/2026
The Qatar Football Association (QFA), in cooperation with Sponix and broadcaster...
08/06/2026
Project B has announced the appointment of Host Broadcast Services (HBS) as Offi...
08/06/2026
The Buckeyes now produce and stream upwards of 200 sports events annually with a...
08/06/2026
At Spotify, our commitment to the LGBTQIA community is year-round. Through GLOW, our global music program, we celebrate and amplify the contributions of queer ...
08/06/2026
Get Hands-on With Keyboard & Synth Brands
GearExpo UK wouldn't be complete without some synth action, and we've got some of the industry's most ...
08/06/2026
50 popular in-ear monitoring system profiles added
The latest update for IK Multimedia's headphone-correction system has just arrived, and introduces ca...
08/06/2026
Manny Marroquin signature cans upgraded with SLAM Technology
The flagship model in Audeze's Manny Marroquin Signature Series has just been treated to an...
08/06/2026
Air domain supremacy redefined - New counter UAS, space solutions and directiona...
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
